Search results

1. Boehringer takes on AbbVie in a novel checkpoint

   … Huadong Medicine PTPN2 inhibitor Preclinical data at ASCO 2024 Unnamed CD3 PTPN1/2 dual inhibitor …

   
    

   Madeleine Armstrong
    
   - 07/30/2024 - 15:58

2. Hookipa hopes for a head and neck fast track

   … 37% 53% CR rate 11% 18% Source: ASCO 2024. Data insights Trial …

   
    

   Madeleine Armstrong
    
   - 07/25/2024 - 13:39

3. Bristol overtakes Amgen in colorectal

   … 2022 based on Krystal-1; confirmatory Krystal-12 data at ASCO 2024 Ph3 Krystal-7, data due 2028 AA 2L Jun 2024 …

   
    

   Madeleine Armstrong
    
   - 06/25/2024 - 13:42

4. ASCO 2024 movers – Affimed wins, Caribou loses

   ASCO 2024 movers – Affimed wins, Caribou loses … tumbling 26%. Several other stocks moved yesterday too, but ASCO 2024’s most significant biotech beneficiary is …

   
    

   Jacob Plieth
    
   - 06/10/2024 - 16:07

5. ASCO 2024 – Yervoy makes the difference in front-line liver cancer

   ASCO 2024 – Yervoy makes the difference in front-line …

   
    

   Jacob Plieth
    
   - 06/21/2024 - 15:49

6. ASCO 2024 – AstraZeneca’s GPC3 secret sauce

   ASCO 2024 – AstraZeneca’s GPC3 secret sauce …

   
    

   Jacob Plieth
    
   - 06/06/2024 - 19:22

7. ASCO 2024 – J&J shifts to a new radiopharma dosing strategy

   ASCO 2024 – J&J shifts to a new radiopharma dosing …

   
    

   Madeleine Armstrong
    
   - 06/04/2024 - 17:26

8. ASCO 2024 – IDRx shoots for an early-line gist

   ASCO 2024 – IDRx shoots for an early-line gist … with IDRX-42 in GIST Venue CTOS Nov 2023 ASCO 2024 abstract May 2024 ASCO 2024 presentation Jun 2024 Cutoff date 5 …

   
    

   Madeleine Armstrong
    
   - 06/04/2024 - 16:14

9. ASCO 2024 – two more Echelon-3 surprises

   ASCO 2024 – two more Echelon-3 surprises …

   
    

   Jacob Plieth
    
   - 06/03/2024 - 00:48

10. ASCO 2024 – Pfizer’s KAT6 inhibitor purrs

    ASCO 2024 – Pfizer’s KAT6 inhibitor purrs …

    
     

    Madeleine Armstrong
     
    - 06/03/2024 - 00:47